D Mark Pritchard

Plain English
Researchers studied how to better predict and prevent harmful reactions to new drugs, known as adverse drug reactions (ADRs). They developed advanced mathematical models that analyze data about drug safety, focusing on the effects of drugs on key body systems like the heart and liver. These models showed promise in identifying risks early, which is critical for safer drug development. Who this helps: This benefits patients by reducing the chances of experiencing harmful side effects from new medications.

Plain English
This study looked at the effectiveness of a treatment called contact x-ray brachytherapy (CXB) for patients with high-risk rectal cancer who have already undergone preliminary chemotherapy and radiation. Researchers followed 328 patients and found that while high-risk patients experienced a higher rate of cancer returning in distant areas (21.2%) compared to lower-risk patients (10.7%), their overall outcomes regarding local tumor control, survival rates, and side effects were similar to those with lower risk. This matters because it shows that CXB can be an effective treatment option for high-risk patients who may not be able to have surgery, allowing them to maintain a certain quality of life while managing their cancer. Who this helps: This helps patients with high-risk rectal cancer who are not candidates for surgery.

Plain English
This study examined how a protein called c-REL affects the development of atherosclerosis, a condition where arteries get clogged, particularly in areas where blood flow is disturbed. Researchers found that c-REL increases inflammation and cell growth in blood vessel linings. In experiments with mice, removing c-REL reduced plaque build-up significantly, suggesting that targeting this protein could be an effective way to treat atherosclerosis. Who this helps: This benefits patients at risk of heart disease due to atherosclerosis.

Plain English
This study looked at the long-term outcomes of patients with early rectal cancer who had a specific type of surgery called transanal endoscopic microsurgery (TEMS) and needed additional treatments due to poor prognostic factors. Among 117 patients treated, 5-year survival rates were 78.6% overall, and 70.9% remained disease-free. It was found that patients who received a combination of chemoradiotherapy and contact X-ray therapy had a significantly lower risk of cancer recurrence compared to those who underwent total mesorectal excision. Who this helps: This research benefits patients with early rectal cancer who may face adverse treatment features after surgery.

Plain English
This research paper focused on how to manage the stomach and digestive issues that often arise from cancer treatments. The study resulted in 103 practical recommendations for doctors to help patients handle these symptoms effectively, which can greatly impact their quality of life. Managing these side effects properly is crucial because up to 25% of cancer survivors experience long-term gastrointestinal issues that can interfere with their treatment and well-being. Who this helps: Patients undergoing cancer treatment and their healthcare providers.

Plain English
This study looked at a new treatment for rectal cancer called Contact X-ray Brachytherapy (CXB) and found that it can help many patients avoid major surgery. In a review of 52 studies involving over 5,400 patients, 82% experienced a complete response to treatment, while 81% were able to preserve their organs without losing them to surgery. This matters because it gives patients with rectal cancer a less invasive option that can still effectively control their disease. Who this helps: This benefits patients with rectal cancer, especially those unable or unwilling to undergo major surgery.

Plain English
This research reviewed past attempts to predict how rectal cancer patients respond to a specific type of radiation therapy called Contact X-ray brachytherapy (CXB). The study found that existing models could predict treatment response fairly well, with one model showing an accuracy rate of 82% and another at 76%, but many of these models have biases and do not apply to a broad enough group of patients. This matters because accurate predictions could lead to better treatment plans and outcomes for patients undergoing this therapy. Who this helps: Patients with rectal cancer and doctors treating them.

Plain English
This study looked at how a specific treatment for rectal cancer, called contact X-ray brachytherapy (CXB), affects patients' health and quality of life over a year. Researchers tracked 53 patients and found that, overall, their quality of life remained stable, with notable improvements in issues like abdominal pain, flatulence, urinary frequency, and body weight after 12 months. Understanding these outcomes helps patients and their doctors make informed choices about using CXB for treatment. Who this helps: This helps rectal cancer patients and their healthcare providers.

Plain English
This study looked at the long-term results for 323 patients with early-stage rectal cancer who received a type of radiation treatment called Contact X-ray Brachytherapy (CXB) combined with external beam radiation after having their tumors surgically removed. The findings showed that 84.2% of patients were alive five years later, and 91.6% were free of cancer recurrence after three years. The research highlights that having cancer cells present at the edges of the removed tissue significantly increased the risk of the cancer coming back. Who this helps: Patients with early-stage rectal cancer who prefer non-invasive treatments.

Plain English
This paper studies neuroendocrine tumors (NENs) in the digestive system, which are becoming more common and are not as rare as once thought. It highlights that these tumors can be well differentiated or poorly differentiated, requiring thorough tests to determine their characteristics and how to treat them. Management varies, with localized cases often needing surgery and advanced cases using hormone therapies; experts recommend that a team of specialists is involved in treatment. Who this helps: This benefits patients with neuroendocrine tumors and the doctors who treat them.

Plain English
This study looked at how patients with gastroenteropancreatic neuroendocrine tumors in the UK feel about getting their medication, lanreotide, at home versus in the hospital. The results showed that 98.7% of the 80 patients surveyed preferred receiving their treatment at home, with many reporting improved quality of life and increased comfort when managing their own treatment. This matters because it highlights that home administration can lead to greater patient satisfaction and may reduce healthcare costs and stress. Who this helps: This helps patients dealing with gastroenteropancreatic neuroendocrine tumors.

Plain English
This study focused on creating a comprehensive care plan for patients with neuroendocrine neoplasms (NENs), a type of cancer that often goes undiagnosed due to low awareness among doctors and limited access to specialized care. Researchers identified significant barriers to care and developed a structured approach to improve management for these patients. Implementing this care pathway across England can lead to better and fairer treatment for all patients with NENs. Who this helps: This benefits patients with neuroendocrine neoplasms and their healthcare providers.

Plain English
This study looked at a treatment called contact X-ray brachytherapy (CXB) for rectal cancer patients who had their tumors come back after trying a "watch-and-wait" approach instead of surgery. Out of 56 patients treated with CXB, 48% of those with early-stage tumor re-growth went into complete remission, while the overall survival rates were 69% after one year and 51% after five years. This treatment provides a viable option for patients who cannot or do not want to undergo surgery, and it helps manage symptoms effectively with few side effects. Who this helps: This benefits rectal cancer patients who experience tumor re-growth and are not fit for or refuse surgery.

Plain English
Researchers studied the best order to give two types of radiation treatment—Contact X-ray Brachytherapy (CXB) and External Beam Radiation Therapy (EBRT)—to patients with small rectal cancer tumors (3 cm or less). They found that starting with CXB led to a better overall survival rate after three years (85%) compared to starting with EBRT (77%), but patients who began with CXB experienced more rectal bleeding (26% had mild bleeding and 6% had moderate bleeding). This study is important because it helps doctors decide on the most effective treatment sequence while balancing the risk of side effects. Who this helps: This helps patients with small rectal cancer by providing better treatment options.

Plain English
This study examined how different gut bacteria in people with irritable bowel syndrome (IBS) affect their response to a low FODMAP diet, which is known to help reduce symptoms. Out of 56 people with IBS, half had a specific type of gut bacteria (IBS-P), which responded better to the diet, showing a significant decrease in pain and symptoms compared to another group (IBS-H) that resembled healthy individuals. The findings indicate that understanding a person's gut bacteria could help tailor dietary treatments, improving outcomes for those likely to benefit most. Who this helps: Patients with irritable bowel syndrome.

Plain English
This study looked at how well tiny laboratory-grown versions of intestines (organoids) imitate the real gut's reaction to a cancer drug called 5-fluorouracil (5-FU). Researchers found that mice given this drug developed diarrhea and other intestinal damage in a dose-dependent way, particularly showing problems at doses of 20 and 50 mg/kg. The organoids reacted similarly to 5-FU, confirming they can be a useful model for studying gut responses to harmful substances. Who this helps: This benefits researchers and doctors looking for better ways to understand and predict drug effects on human intestines.

Plain English
This study investigated how a protein called galectin-3 affects colon cancer cells. It found that galectin-3 triggers these cancer cells to release substances called proteases, which damage the protective lining in the colon and help cancer spread. Specifically, the study showed that secreting galectin-3 leads to the release of proteases like cathepsin-B and MMP-1, disrupting normal cell integrity and promoting invasion. Who this helps: This research benefits cancer patients by highlighting a target for new treatments.

Plain English
This guidance paper looks at how doctors should identify and treat certain types of neuroendocrine tumors (NETs) located in the stomach and the beginning of the small intestine, focusing on well-differentiated tumors classified as G1-G3. The updated guidelines aim to equip specialists with practical recommendations for managing these tumors effectively. This matters because having clear guidelines can help improve patient outcomes and ensure consistent care for those with these specific tumors. Who this helps: This helps patients with gastroduodenal neuroendocrine tumors and their healthcare providers.

Plain English
Researchers created a model to predict how certain cancer drugs might harm the intestines. They found that two chemotherapy drugs, doxorubicin and 5-fluorouracil, can cause damage to the intestinal lining in mice, which can lead to symptoms like diarrhea. The model was effective at estimating the risk of these side effects in humans based on mouse data, showing that the approach could be valuable in predicting drug safety during early drug development. Who this helps: Patients undergoing cancer treatment.

Plain English
This study focused on how the intestinal lining in mice maintains its structure and recovers from damage, using a specially designed computer model. The researchers found that certain biological signals interact in complex ways to help cells grow and repair themselves; for example, when DNA damage from chemotherapy was simulated, it affected the cells' ability to function normally and maintain the intestinal barrier. Importantly, the model showed how the intestinal tissue can recover from this damage through self-reorganization, which is crucial for understanding treatments for intestinal diseases. Who this helps: This research benefits patients undergoing chemotherapy and those with intestinal disorders.

Plain English
The research paper discusses neuroendocrine tumors (NETs), which are complex cancers that gastroenterologists sometimes help diagnose and treat, even though many lack detailed training on the subject. It emphasizes that these tumors can be hard to identify, leading to significant delays in diagnosis for patients. The paper highlights that treatment options vary widely, with monthly injections of a medication called somatostatin being the common first choice for patients with metastatic low-grade NETs; while some can live for many years with good quality of life, others may face chronic gastrointestinal issues. Who this helps: This information benefits gastroenterologists and their patients dealing with neuroendocrine tumors.

Plain English
This study focused on gastric neuroendocrine neoplasms (g-NENs), a rare type of stomach cancer, and found that there are different subtypes that behave in unique ways and need different treatment approaches. Researchers discovered a new genetic mutation linked to some familial cases and identified new biomarkers that could lead to better diagnosis and treatment strategies. This matters because it can improve how doctors manage these cancers, especially by allowing less aggressive treatments for patients with slower-growing tumors. Who this helps: This benefits patients with gastric neuroendocrine neoplasms and their healthcare providers.

Plain English
This study looked at how our understanding of a specific stomach infection has changed since it was first discovered in 1984. Researchers found that while some treatment practices are now outdated, the infection still poses a significant global health risk, as it can lead to stomach cancer, which remains a major cause of death. Because the infection is becoming harder to treat due to antibiotic resistance, it is crucial for doctors to check whether treatments are working and to monitor patients for early signs of cancer. Who this helps: Patients at risk of stomach infections and associated cancers.

Plain English
This study focuses on a protein called MMP-13, which is found in low amounts in healthy conditions but is increased in many types of cancer. Researchers found that MMP-13 helps tumors grow and spread by breaking down the surrounding tissue and releasing factors that encourage cancer cell growth and the formation of new blood vessels. Understanding how MMP-13 works is important because it could lead to new ways to treat cancer more effectively. Who this helps: This helps patients with cancer and their doctors.

Plain English
This study looked at patients with small type I gastric neuroendocrine tumors (under 10 mm) to see if monitoring them with endoscopic procedures instead of immediate treatment was safe and effective. Out of 115 patients, 87 were monitored without treatment, and 91% showed no significant changes in their tumors over an average of about 5 years. This is important because it suggests that many patients with small tumors may not need surgery, allowing for less invasive management while still keeping an eye on any potential changes. Who this helps: This benefits patients with small gastric neuroendocrine tumors and their doctors by reducing the need for surgery and frequent procedures.

Plain English
This study looked at how a specific deficiency in mice affects their immune system, particularly in the small intestine. The researchers found that this deficiency led to very low levels of immunoglobulin A (0% detected) and a significant increase in immunoglobulin M, along with fewer antibody-producing plasma cells. Understanding these changes is important because it helps explain why these mice were more resistant to certain intestinal damages, indicating a complex relationship between immune cell function and gut health. Who this helps: This benefits researchers and doctors working on gastrointestinal diseases and immune system disorders.

Plain English
This study focuses on understanding how well patients with rectal cancer respond to radiotherapy so that treatments can be tailored to individual needs. The researchers plan to review published models that predict treatment response, looking at factors like surgery outcomes one year after therapy. They aim to determine which prediction models are most accurate and useful, which could help improve patient treatment strategies. Who this helps: This helps patients with rectal cancer and their doctors by providing better guidance on treatment options.

Plain English
The study looked at patients with small, non-functioning duodenal neuroendocrine tumors (d-NETs) to see if a "watch and wait" approach, which involves regular check-ups instead of immediate surgery, is safe. Out of 30 patients who chose this approach, 28 had stable or shrinking tumors over a median follow-up of 27 months, and no patients died from their tumors. This matters because it offers a less invasive option for managing certain d-NETs that are unlikely to cause serious problems. Who this helps: This benefits patients with small, localized d-NETs who are seeking less aggressive treatment options.

Plain English
This study looked at how lymph nodes and a specific surgery (right hemicolectomy) affect the outcomes for patients with appendiceal neuroendocrine tumors (aNETs). Researchers followed 102 patients over many years and found that most survived long-term, with a 5-year survival rate of 99% and a 10-year survival rate of 92%. The study highlights that these tumors generally grow slowly, with few patients experiencing a recurrence many years later, which suggests that regular monitoring might be more beneficial than aggressive surgery for some patients. Who this helps: This information helps patients with aNETs and their doctors make informed decisions about treatment and follow-up care.

Plain English
Researchers studied the effects of different levels of dietary iron on gut inflammation in mice with colitis. They found that mice on a low iron diet lost more weight and showed more signs of inflammation during acute flare-ups compared to those with normal or high iron diets. Although long-term dietary iron changes didn’t worsen chronic colitis, certain gut bacteria patterns shifted with high iron levels, which may contribute to changes in the disease. Who this helps: This research helps patients with inflammatory bowel disease (IBD) and their doctors.

Plain English
This study looked at patients with a rare and aggressive type of cancer called appendiceal goblet cell carcinoma (aGCC). The researchers found that out of 41 patients treated, the overall survival rates were 85.3% after five years and 62.3% after ten years, but the presence of recurrence was significant, with about 9 out of 41 patients experiencing it. Completion surgery did not seem to help improve survival rates or prevent recurrences. Who this helps: Patients with appendiceal goblet cell carcinoma and their doctors.

Plain English
This study focused on the treatment of grade 1 or 2 type III gastric neuroendocrine neoplasms (g-NENs), which are tumors in the stomach. Researchers analyzed 45 patients and found that those with tumors larger than 10 millimeters had worse outcomes and were more likely to have lymph node spread. The results showed that smaller tumors could be safely treated with less invasive procedures rather than major surgery. Who this helps: This helps patients with early-stage gastric neuroendocrine tumors who may benefit from less invasive treatment options.

Plain English
This study looked at how well Gallium DOTA PET/CT scans help in managing patients with pancreatic neuroendocrine tumors (panNETs), which can occur randomly or due to genetic factors. Researchers analyzed data from 183 patients and found that these scans provided useful information for 54% of patients and changed treatment plans for 39% of them. Specifically, the scans revealed new areas of disease in nearly 29% of the patients and confirmed previous imaging results in 53% of cases, making them a valuable tool for better diagnosis and treatment of this type of cancer. Who this helps: Patients with pancreatic neuroendocrine tumors.

Plain English
The study looked at how two iron supplements, ferric maltol (FM) and ferrous sulphate (FS), affect gut bacteria in mice with colitis and in patients with iron deficiency. It found that FS worsened gut issues and changed the gut bacteria in mice, while FM did not adversely affect the bacteria and improved gut health. For patients, those taking FS showed changes in gut bacteria, while FM did not cause any changes, highlighting that FM might be a safer option for people needing iron without harming gut health. Who this helps: Patients with iron deficiency, especially those with gut issues.

Plain English
This study looked at how a protein called peanut agglutinin (PNA) found in peanuts affects blood vessels after eating peanuts. The researchers found that PNA leads to the release of certain signals (cytokines) that can promote cancer spread. Specifically, they discovered that PNA increases the production of cytokines MCP-1 and IL-6, which enhance cancer cells' ability to stick to blood vessels and grow. Who this helps: This research benefits patients with cancer by highlighting how certain foods might influence cancer spread.

Plain English
This study compared different ways of diagnosing and treating stomach issues to find the most cost-effective method for patients in the UK. It evaluated a "test-and-treat" approach using the urea breath test (UBT) and found it to be very cost-effective, costing around €526 per patient treated successfully, compared to €1,317 for an endoscopy-based approach. This matters because using UBT can lead to better management of dyspepsia symptoms and prevent peptic ulcers while saving money in the healthcare system. Who this helps: This helps patients dealing with stomach issues and healthcare providers looking for effective treatment options.

Plain English
This research paper discusses how to manage iron deficiency anemia (IDA), a common condition where the body lacks enough iron, leading to health problems. It was found that about one-third of men and postmenopausal women with IDA have an underlying issue, often related to the gastrointestinal tract, which can include serious conditions like cancer. The updated guidelines help doctors ensure proper diagnosis and treatment, emphasizing the need for testing and iron replacement therapy. Who this helps: This benefits patients suffering from iron deficiency anemia and healthcare professionals managing their care.

Plain English
This study looks at a rare case where a 62-year-old woman showed signs of stomach cancer, but later it was found that she actually had metastatic breast cancer that had spread to her stomach before her primary breast cancer was diagnosed. Initially, stomach cancer was suspected, but tests revealed it was metastatic lobular breast carcinoma. After treatment, her symptoms improved, which highlights the importance of recognizing this possibility to ensure timely and accurate diagnosis. Who this helps: This helps patients with rare cancer presentations and doctors in making more accurate diagnoses.

Plain English
This study looked at how genetics might influence the development of stomach ulcers in people taking low-dose aspirin. Researchers found that a specific genetic variation (called rs12678747) in the EYA1 gene significantly increases the risk of developing these ulcers; individuals with this variant were more than twice as likely to develop aspirin-induced peptic ulcers (with an odds ratio of 2.03). Understanding these genetic links can help identify patients at higher risk and lead to better management of aspirin use for those who might be more susceptible. Who this helps: This helps patients who take aspirin and may be at risk of developing peptic ulcers, as well as their doctors.

Plain English
This study looked at how certain factors like proton pump inhibitors (PPIs), infections, and pre-cancerous changes in the stomach affect levels of a hormone called gastrin in the blood. Researchers measured gastrin levels in 982 patients, finding that those taking PPIs had higher gastrin levels (46 picomoles) compared to healthy individuals (20 picomoles), and those with stomach pre-cancer (48 picomoles). Understanding these relationships is important because it helps doctors determine whether a high gastrin level is due to benign causes or something more serious. Who this helps: This research benefits doctors assessing patients for stomach issues.

Plain English
This study looked at how long-term use of certain drugs and infections change the balance of bacteria in the stomach. Researchers found that using advanced analysis techniques revealed hidden patterns in bacterial behavior that traditional methods missed, helping to uncover how these bacteria and their associated metabolites interact when the stomach environment is disturbed. Understanding these changes is important because it can lead to better insights into gastric health and treatment strategies. Who this helps: This benefits patients with gastric issues related to medication or infections, as well as doctors working to improve treatment outcomes.

Plain English
This study looked at how adding a new medication, telotristat ethyl, to the standard treatment for patients with uncontrolled carcinoid syndrome— a rare condition that causes severe symptoms like flushing and diarrhea—could affect healthcare costs in Sweden over five years. They found that while the costs for telotristat ethyl treatment would rise initially, overall expenses would actually decrease from €66,495 in the first year to €29,818 by the fifth year, resulting in a total savings of €172,346. This is important because it shows that the new treatment could improve patients’ quality of life without significantly increasing healthcare costs. Who this helps: This helps patients with uncontrolled carcinoid syndrome who need better symptom management.

Plain English
This study looked at how to best treat localized, low-grade neuroendocrine tumors (NETs) in the stomach and duodenum, which are rare but becoming more common. It found that type I gastric NETs have a great outlook and often can be managed with monitoring or endoscopic removal; endoscopic methods were also safe for smaller, low-grade duodenal NETs. However, some patients, especially those with larger tumors, still need traditional surgery. Who this helps: This benefits patients with low-grade NETs by providing safer treatment options.

Plain English
This study looked at a specific protein called NAP1L1 to see if it could serve as a helpful indicator for colorectal cancer (CRC). Researchers found that NAP1L1 levels were lower in cancerous tissue compared to normal tissue, and they noticed that higher levels of NAP1L1 in stage III and IV CRC patients were linked to better survival rates. These findings are important because they could lead to a new way of predicting outcomes for patients with advanced colorectal cancer. Who this helps: This helps patients with colorectal cancer and their doctors in understanding prognosis and potential treatment outcomes.

Plain English
This study looked at existing medications that could help treat inflammatory bowel disease (IBD) by targeting a specific signaling pathway called NF-κB, which is known to be involved in these conditions. The researchers found that the antibiotic clarithromycin was particularly effective in changing NF-κB activity and reducing inflammation in both mouse models and human intestinal cells. This is important because clarithromycin might provide a new treatment option for patients with IBD, who currently have limited choices. Who this helps: Patients suffering from inflammatory bowel disease.

Plain English
This study looked at how often patients without neuroendocrine tumors (NETs) show false-positive results for gut hormone tests, which are typically used to check for these tumors. Out of 231 patients tested, 31 showed false-high gastrin levels, 8 had false high levels of chromogranin A, and smaller numbers had false highs for other hormones. The study found that some medications and not fasting properly were common reasons for these misleading results, which can lead to unnecessary worry and treatment. Who this helps: This helps patients and doctors by clarifying the reasons behind false-positive test results and reducing unnecessary stress and procedures.